Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
IDXX · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortIDEXX LABORATORIES INC /DE is profitable, generates cash and carries moderate debt, with revenue growing (+10.4% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 31.6% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 24.6% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 66.2% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 52.9% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.23× | 36/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.28× | 96/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.18× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 35.01× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 10.43 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 24.6% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.00× | 87/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 5.5% | 91/100 |
| Operating margin volatility | 1.8% | 93/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 8.5% | 64/100 |
|---|---|---|
| EPS growth, 3-year average | 17.7% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 |
| Cost of revenue | 1,326 | 1,363 | 1,471 | 1,519 | 1,644 |
| Gross profit | 1,889 | 2,004 | 2,190 | 2,379 | 2,660 |
| Research & development | 161 | 255 | 191 | 220 | 251 |
| Operating income | 932 | 899 | 1,097 | 1,128 | 1,360 |
| Interest expense | 30 | 40 | 42 | 31 | 39 |
| Pre-tax income | 903 | 860 | 1,061 | 1,110 | 1,324 |
| Income tax | 158 | 181 | 216 | 222 | 265 |
| Net income | 745 | 679 | 845 | 888 | 1,059 |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Diluted shares (millions) | 87 | 85 | 84 | 83 | 81 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of IDEXX LABORATORIES INC /DE are included in the Investor plan. Try free for 7 days →
10.43 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026